定义COVID-19相关肺曲霉病:系统综述与荟萃分析
该研究系统检索至2021年10月12日,纳入51项ICU队列研究与CAPA病例系列;ICU队列中CAPA患病率为10%(95%CI 8%-13%),患者病死率59.2%,不同研究定义间相关性有限,33.9%被报告为CAPA的患者不符合任何研究定义。
要点
- ICU队列中COVID-19患者CAPA患病率为10%(95%CI 8%-13%)。
- CAPA患者病死率为59.2%。
- 33.9%被报告为CAPA的患者不符合任何研究定义。
核心结论
- 报告的CAPA患病率显著,但可能因非标准定义而被夸大。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Embase、Web of Science和MedRxiv从建库至2021年10月12日。
- 纳入ICU队列研究和包含≥3例患者的CAPA病例系列,对象为ICU成年COVID-19患者。
- 共纳入51项研究;ICU队列研究含3297例COVID-19患者,其中313例诊断为CAPA;277例有患者层面数据可供重新分类。
主要发现
- ICU队列研究中CAPA患病率为10%(95%CI 8%-13%)。
- 不同定义间相关性有限(ρ=0.268-0.447;p<0.001),但Koehler与Verweij定义间例外(ρ=0.893;p<0.001)。
- 33.9%被报告为CAPA的患者不符合任何研究定义。
- 患者在ICU中诊断的中位时间为8天(四分位距5-14天)。
- 接受支气管镜检查的患者中气管支气管炎发生率为3%;病死率为59.2%。
关键数值与推荐
- CAPA患病率采用Freeman-Tukey随机效应法计算。
- 定义间相关性采用Spearman秩和检验评估。
- 抗真菌药物与结局的关联采用随机效应荟萃分析评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pulmonary aspergillosis may complicate coronavirus disease 2019 (COVID-19) and contribute to excess mortality in intensive care unit (ICU) patients. The disease is poorly understood, in part due to discordant definitions across studies. OBJECTIVES: We sought to review the prevalence, diagnosis, treatment, and outcomes of COVID-19-associated pulmonary aspergillosis (CAPA) and compare research definitions. DATA SOURCES: PubMed, Embase, Web of Science, and MedRxiv were searched from inception to October 12, 2021. STUDY ELIGIBILITY CRITERIA: ICU cohort studies and CAPA case series including ≥3 patients were included. PARTICIPANTS: Adult patients in ICUs with COVID-19. INTERVENTIONS: Patients were reclassified according to four research definitions. We assessed risk of bias with an adaptation of the Joanna Briggs Institute cohort checklist tool for systematic reviews. METHODS: We calculated CAPA prevalence using the Freeman-Tukey random effects method. Correlations between definitions were assessed with Spearman's rank test. Associations between antifungals and outcome were assessed with random effects meta-analysis. RESULTS: Fifty-one studies were included. Among 3297 COVID-19 patients in ICU cohort studies, 313 were diagnosed with CAPA (prevalence 10%; 95% CI 8%-13%). Two hundred seventy-seven patients had patient-level data allowing reclassification. Definitions had limited correlation with one another (ρ = 0.268-0.447; p < 0.001), with the exception of Koehler and Verweij (ρ = 0.893; p < 0.001); 33.9% of patients reported to have CAPA did not fulfill any research definitions. Patients were diagnosed after a median of 8 days (interquartile range 5-14) in ICUs. Tracheobronchitis occurred in 3% of patients examined with bronchoscopy. The mortality rate was high (59.2%). Applying CAPA research definitions did not strengthen the association between mould-active antifungals and survival. CONCLUSIONS: The reported prevalence of CAPA is significant but may be exaggerated by nonstandard definitions.
引用
- Kariyawasam RM, Dingle TC, Kula BE, et al. Defining COVID-19-associated pulmonary aspergillosis: systematic review and meta-analysis. Clin Microbiol Infect. 2022. PMID: 35150878. doi:10.1016/j.cmi.2022.01.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。